0001415889-24-019976.txt : 20240723 0001415889-24-019976.hdr.sgml : 20240723 20240723181303 ACCESSION NUMBER: 0001415889-24-019976 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240722 FILED AS OF DATE: 20240723 DATE AS OF CHANGE: 20240723 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: White Ted CENTRAL INDEX KEY: 0001741964 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 241135708 MAIL ADDRESS: STREET 1: C/O VERRICA PHARMACEUTICALS INC. STREET 2: 10 NORTH HIGH STREET, SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 4 1 form4-07232024_100700.xml X0508 4 2024-07-22 0001660334 Verrica Pharmaceuticals Inc. VRCA 0001741964 White Ted C/O VERRICA PHARMACEUTICALS INC. 44 WEST GAY STREET, SUITE 400 WEST CHESTER PA 19380 true true false false PRESIDENT AND CEO 0 Common Stock 2024-07-22 4 S 0 32469 7.06 D 250121 D Common Stock 2024-07-23 4 S 0 154 6.98 D 249967 D Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mark Ballantyne, Attorney-in-Fact 2024-07-23